Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation?
- 1 January 1993
- journal article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 36 (1) , 45-51
- https://doi.org/10.1007/bf01789130
Abstract
The purpose of this study was to determine the effects of ibuprofen on the ability of liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) to activate human blood monocytes in vitro. We undertook these experiments because the major toxic side-effects following L-MTP-PE infusion, fever and chills, could be prevented when ibuprofen was given orally immediately before L-MTP-PE infusion. It was therefore important to determine whether ibuprofen interfered with the macrophage-activation properties of L-MTP-PE. Peripheral blood monocytes were isolated from normal donors, then incubated with L-MTP-PE in the presence or absence of ibuprofen. The cytotoxic properties of the monocytes were assessed by a radioisotope-release assay against A375 cells. Ibuprofen at dose levels of 40 µg/ml suppressed the generation of the cytotoxic phenotype but did not interfere with the killing process once the cells were activated. Interleukin-1 (IL-1) and tumor necrosis factor α (TNFα) production, as well as the mRNA expression of these cytokines, was suppressed by 40 µg/ml ibuprofen. Since IL-1 and TNF play a crucial role in the cytotoxic function of monocytes, these findings may explain the mechanism by which ibuprofen inhibited the generation of the cytotoxic phenotype by L-MTP-PE. By contrast, ibuprofen dose levels up to 10 µg/ml had no effect on the generation of monocyte-mediated cytotoxicity by L-MTP-PE and no effect on the production, secretion, or mRNA expression of TNF and IL-1. Therefore, we concluded that if ibuprofen is to be used to control the side-effects of L-MTP-PE, blood levels of up to 10 µg/ml are desirable. In two of three patients, we determined that an oral dose of 200 mg given immediately before L-MTP-PE infusion could achieve these desired blood levels.Keywords
This publication has 24 references indexed in Scilit:
- Therapy for Osteosarcoma in Dogs With Intravenous Injection of Liposome-Encapsulated Muramyl TripeptideJNCI Journal of the National Cancer Institute, 1989
- The influence of sucralfate on ibuprofen absorption in healthy adult malesBiopharmaceutics & Drug Disposition, 1986
- Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.Proceedings of the National Academy of Sciences, 1986
- Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in VitroScience, 1985
- Tumor Necrosis Factor (TNF)Science, 1985
- Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells.The Journal of Experimental Medicine, 1983
- Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines.Journal of Clinical Investigation, 1983
- Prostaglandin E2 modulation of human monocyte antibody-dependent cell-mediated cytotoxicity against human red blood cellsCellular Immunology, 1982
- Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.Proceedings of the National Academy of Sciences, 1981
- The effects of experimental conditions on the expression of in vitro-mediated tumor cytotoxicity mediated by murine macrophagesCancer Immunology, Immunotherapy, 1979